Redox signaling in drug-tolerant persister cells as an emerging therapeutic target

EBioMedicine. 2023 Mar:89:104483. doi: 10.1016/j.ebiom.2023.104483. Epub 2023 Feb 22.

Abstract

Drug-tolerant persister (DTP) cells have attracted significant interest, given their predominant role in treatment failure. In this respect, DTP cells reportedly survive after anticancer drug exposure, and their DNA repair mechanisms are altered to enhance adaptive mutation, accounting for the emergence of drug-resistant mutations. DTP cells resume proliferation upon treatment withdrawal and are responsible for cancer relapse. Current evidence suggests that DTP cells mediate redox signaling-mediated cellular homeostasis by developing various adaptive mechanisms, especially metabolic reprogramming that promotes mitochondrial oxidative respiration and a robust antioxidant process. There is an increasing consensus that disrupting redox homeostasis by intervening with redox signaling is theoretically a promising therapeutic strategy for targeting these sinister cells. In this review, we provide a comprehensive overview of the characteristics of DTP cells and the underlying mechanisms involved in redox signaling, aiming to provide a unique perspective on potential therapeutic applications based on their vulnerabilities to redox regulation.

Keywords: Cancer relapse; Drug resistance; Drug-tolerant persister; Redox homeostasis; Redox signaling.

Publication types

  • Review

MeSH terms

  • Antioxidants*
  • Humans
  • Oxidation-Reduction
  • Signal Transduction*

Substances

  • Antioxidants